![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/LALPATHLAB.png)
Share the post "Dr Lal Path Labs ‘s Q3 2024-25 Latest News: Profit Up by 29.67% Year-on-Year"
Highlights
🔹 The presented financial data is Standalone to provide a comprehensive overview of the company performance. 🔹 Sales over the Year and quarter: The company experienced a substantial growth of 10.95 % in the past year, decrease in net sales/revenue by -9.56 %. 🔹 Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 95.36 %. Marginal increase in other income during this quarter, up by 34.09%. 🔹 Profit over the Year and quarter: Significant improvement in profitability for Dr. Lal Path Labs Ltd.. Notable increase of 29.67 % in net profit Year to Year, Dr. Lal Path Labs Ltd.’s profitability dropped by -15.31 % Quarter to Quarter. 🔹 EPS over the Year and quarter: EPS increased by 27.46 % Year to Year. EPS decreased by -15.39 % in previous quarter. Analysis needed for shareholder value.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 476 Cr | Rs. 583.9 Cr | Rs. 528.1 Cr | -9.56 % | + 10.95 % |
| Expenses | Rs. 345.9 Cr | Rs. 399.4 Cr | Rs. 382.7 Cr | -4.18 % | + 10.64 % |
| Operating Profit | Rs. 130.1 Cr | Rs. 184.5 Cr | Rs. 145.4 Cr | -21.19 % | + 11.76 % |
| OPM % | 27.33 % | 31.6 % | 27.53 % | -4.07 % | + 0.2 % |
| Other Income | Rs. 15.1 Cr | Rs. 22 Cr | Rs. 29.5 Cr | + 34.09 % | + 95.36 % |
| Interest | Rs. 6.5 Cr | Rs. 5 Cr | Rs. 4.8 Cr | -4 % | -26.15 % |
| Depreciation | Rs. 19.2 Cr | Rs. 18.2 Cr | Rs. 18.9 Cr | + 3.85 % | -1.56 % |
| Profit before tax | Rs. 119.5 Cr | Rs. 183.3 Cr | Rs. 151.2 Cr | -17.51 % | + 26.53 % |
| Tax % | 26.11 % | 26.24 % | 24.27 % | -1.97 % | -1.84 % |
| Net Profit | Rs. 88.3 Cr | Rs. 135.2 Cr | Rs. 114.5 Cr | -15.31 % | + 29.67 % |
| EPS in Rs | Rs. 10.75 | Rs. 16.2 | Rs. 13.71 | -15.37 % | + 27.53 % |
Today, we’re looking at Dr. Lal Path Labs Ltd.’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a robust year-over-year sales growth of 10.95 %. However, it did see a marginal slip of -9.56 % from the previous quarter. Expenses decreased slightly by -4.18 % quarter-on-quarter, aligning with the annual rise of 10.64 %. Operating profit, while up 11.76 % compared to last year, faced a quarter-on-quarter dip of -21.19 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 0.2 %, but a shrinkage of -4.07 % sequentially. Other income rose by 34.09 % compared to the last quarter, despite an annual growth of 95.36 %. Interest expenses dropped significantly by -4 % from the previous quarter, yet the year-over-year decrease remains at a moderate -26.15 %. Depreciation costs climbed by 3.85 % quarter-on-quarter, yet on an annual scale, they experienced a reduction of -1.56 %. Profit before tax grew annually by 26.53 % but saw a reduction from the preceding quarter by -17.51 %.
Tax expenses as a percentage of profits decreased slightly by -1.84 % compared to last year, with a more notable quarter-on-quarter decrease of -1.97 %. Net profit rose by 29.67 % year-on-year but witnessed a -15.31 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 27.53 % but a quarterly fall of -15.37 %. In summary, Dr. Lal Path Labs Ltd.’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 476 Cr | Rs. 583.9 Cr | Rs. 528.1 Cr | -9.56 % | + 10.95 % |
| Expenses | Rs. 345.9 Cr | Rs. 399.4 Cr | Rs. 382.7 Cr | -4.18 % | + 10.64 % |
| Operating Profit | Rs. 130.1 Cr | Rs. 184.5 Cr | Rs. 145.4 Cr | -21.19 % | + 11.76 % |
| Net Profit | Rs. 88.3 Cr | Rs. 135.2 Cr | Rs. 114.5 Cr | -15.31 % | + 29.67 % |
| EPS in Rs | Rs. 10.75 | Rs. 16.2 | Rs. 13.71 | -15.37 % | + 27.53 % |
In reviewing Dr. Lal Path Labs Ltd.’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 10.95 % year-on-year growth, although there was a slight dip of -9.56 % from the previous quarter. Expenses rose by 10.64 % compared to the previous year, with a decrease of -4.18 % quarter-on-quarter. Operating Profit surged by 11.76 % annually, and saw a -21.19 % decrease from the last quarter.
Net Profit showed yearly increase of 29.67 %, and experienced a -15.31 % decrease from the previous quarter. Earnings Per Share (EPS) rose by 27.53 % annually, however dipped by -15.37 % compared to the last quarter. In essence, while Dr. Lal Path Labs Ltd. exhibits strong annual growth indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/DMART.png)
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/PVP.png)
